The DOI matches its Crossref record; 198 of the 198 references it cites were found in a registry or an index.
Antibody–drug conjugates as novel anti-cancer chemotherapeutics
Open accessAbstract
Over the past couple of decades, antibody–drug conjugates (ADCs) have revolutionized the field of cancer chemotherapy. Unlike conventional treatments that damage healthy tissues upon dose escalation, ADCs utilize monoclonal antibodies (mAbs) to specifically bind tumour-associated target antigens and deliver a highly potent cytotoxic agent. The synergistic combination of mAbs conjugated to small-molecule chemotherapeutics, via a stable linker, has given rise to an extremely efficacious class of anti-cancer drugs with an already large and rapidly growing clinical pipeline. The primary objective of this paper is to review current knowledge and latest developments in the field of ADCs. Upon intravenous administration, ADCs bind to their target antigens and are internalized through receptor-mediated endocytosis. This facilitates the subsequent release of the cytotoxin, which eventually leads to apoptotic cell death of the cancer cell. The three components of ADCs (mAb, linker and cytotoxin) affect the efficacy and toxicity of the conjugate. Optimizing each one, while enhancing the functionality of the ADC as a whole, has been one of the major considerations of ADC design and development. In addition to these, the choice of clinically relevant targets and the position and number of linkages have also been the key determinants of ADC efficacy. The only marketed ADCs, brentuximab vedotin and trastuzumab emtansine (T-DM1), have demonstrated their use against both haematological and solid malignancies respectively. The success of future ADCs relies on improving target selection, increasing cytotoxin potency, developing innovative linkers and overcoming drug resistance. As more research is conducted to tackle these issues, ADCs are likely to become part of the future of targeted cancer therapeutics.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., & McGuire, W. L. (1987) · Science · doi:10.1126/science.3798106 · Cited by 11,760 · cited 1×
“Trastuzumab is a humanized antibody that targets the transmembrane tyrosine kinase receptor, HER2 (a member of the EGFR family) that is commonly overexpressed in a quarter of all breast cancers [63].”
BackgroundNormalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy
Jain, R. K. (2005) · Science · doi:10.1126/science.1104819 · Cited by 5,527 · cited 1×
“ADCs that bind to neovasculature destroy the tumour blood supply and cause tumour cell death via nutrient deprivation and hypoxia [75] [76].”
BackgroundTissue microarrays for high-throughput molecular profiling of tumor specimens
Kononen, J., Bubendorf, L., Kallionimeni, A., Bärlund, M., Schraml, P., Leighton, S., Torhorst, J., Mihatsch, M. J., Sauter, G., & Kallionimeni, O.-P. (1998) · Nature Medicine · doi:10.1038/nm0798-844 · Cited by 4,099
Trastuzumab emtansine for HER2-positive advanced breast cancer
Verma, S., Miles, D., Gianni, L., Krop, I. E., Welslau, M., Baselga, J., Pegram, M., Oh, D.-Y., Diéras, V., Guardino, E., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1209124 · Cited by 3,834 · cited 1×
“The more recent approval of trastuzumab emtansine in 2014, [35] for use against breast cancer, proved that ADCs were capable of targeting solid tumours in addition to haematological malignancies.”
BackgroundDrug penetration in solid tumours
Minchinton, A. I., & Tannock, I. F. (2006) · Nature reviews. Cancer · doi:10.1038/nrc1893 · Cited by 2,805
Mechanisms of Cancer Drug Resistance
Gottesman, M. M. (2002) · Annual Review of Medicine · doi:10.1146/annurev.med.53.082901.103929 · Cited by 2,643 · cited 1×
“Most cytotoxins are susceptible to resistance via an array of mechanisms [202].”
BackgroundFcRn: the neonatal Fc receptor comes of age
Roopenian, D. C., & Akilesh, S. (2007) · Nature Reviews Immunology · doi:10.1038/nri2155 · Cited by 2,346
Scott, A. M., Wolchok, J. D., & Old, L. J. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3236 · Cited by 2,160
Cited by
Exploring treatment options in cancer: tumor treatment strategies
Liu, B., Zhou, H., Tan, L., Siu, K. T. H., & Guan, X.-Y. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01856-7 · Cited by 1,201
Molecular targeted therapy: Treating cancer with specificity
Lee, Y. T., Tan, Y. J., & Oon, C. E. (2018) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2018.07.034 · Cited by 1,067
Antibody–drug conjugates for cancer
Chau, C. H., Steeg, P. S., & Figg, W. D. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31774-x · Cited by 816
Antibody–Drug Conjugates: A Comprehensive Review
Khongorzul, P., Ling, C. J., Khan, F. U., Ihsan, A. U., & Zhang, J. (2020) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-19-0582 · Cited by 787
Nakada, T., Sugihara, K., Jikoh, T., Abe, Y., & Agatsuma, T. (2019) · Chemical and Pharmaceutical Bulletin · doi:10.1248/cpb.c18-00744 · Cited by 442
Mechanisms of ADC Toxicity and Strategies to Increase ADC Tolerability
Nguyen, T. D., Bordeau, B. M., & Balthasar, J. P. (2023) · Cancers · doi:10.3390/cancers15030713 · Cited by 441
Recent progress in development of siRNA delivery vehicles for cancer therapy
Kim, H. J., Kim, A., Miyata, K., & Kataoka, K. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.06.011 · Cited by 424
Metalloproteinases and Their Inhibitors: Potential for the Development of New Therapeutics
Raeeszadeh-Sarmazdeh, M., Do, L., & Hritz, B. (2020) · Cells · doi:10.3390/cells9051313 · Cited by 324
Molecular biomarkers in acute myeloid leukemia
Prada-Arismendy, J., Arroyave, J. C., & Röthlisberger, S. (2017) · Blood Reviews · doi:10.1016/j.blre.2016.08.005 · Cited by 304
Paclitaxel: Application in Modern Oncology and Nanomedicine‐Based Cancer Therapy
Sharifi-Rad, J., Quispe, C., Patra, J. K., Singh, Y. D., Panda, M. K., Das, G., Adetunji, C. O., Michael, O. S., Sytar, O., Polito, L., et al. (2021) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2021/3687700 · Cited by 298
An Insight into FDA Approved Antibody-Drug Conjugates for Cancer Therapy
Tong, J. T. W., Harris, P. W. R., Brimble, M. A., & Kavianinia, I. (2021) · Molecules · doi:10.3390/molecules26195847 · Cited by 287
Antibody–Drug Conjugates (ADCs): current and future biopharmaceuticals
Wang, R., Hu, B., Pan, Z., Mo, C., Zhao, X., Liu, G., Hou, P., Cui, Q., Xu, Z., Wang, W., et al. (2025) · Journal of Hematology & Oncology · doi:10.1186/s13045-025-01704-3 · Cited by 285
Biologics vs. small molecules: Drug costs and patient access
Makurvet, F. D. (2021) · Medicine in Drug Discovery · doi:10.1016/j.medidd.2020.100075 · Cited by 271
How to select IgG subclasses in developing anti-tumor therapeutic antibodies
Yu, J., Song, Y., & Tian, W. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00876-4 · Cited by 269
From Anthramycin to Pyrrolobenzodiazepine (PBD)‐Containing Antibody–Drug Conjugates (ADCs)
Mantaj, J., Jackson, P. J. M., Rahman, K. M., & Thurston, D. E. (2017) · Angewandte Chemie International Edition · doi:10.1002/anie.201510610 · Cited by 262
The Dawn of a New Era: Targeting the “Undruggables” with Antibody-Based Therapeutics
Qian, L., Lin, X., Gao, X., Khan, R. U., Liao, J.-Y., Du, S., Ge, J., Zeng, S., & Yao, S. Q. (2023) · Chemical Reviews · doi:10.1021/acs.chemrev.2c00915 · Cited by 155
LGR5-Targeted Antibody–Drug Conjugate Eradicates Gastrointestinal Tumors and Prevents Recurrence
Gong, X., Azhdarinia, A., Ghosh, S. C., Xiong, W., An, Z., Liu, Q., & Carmon, K. S. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0114 · Cited by 130
Cheng, Y., Thalhauser, C. J., Smithline, S., Pagidala, J., Miladinov, M., Vezina, H. E., Gupta, M., Leil, T. A., & Schmidt, B. J. (2017) · The AAPS Journal · doi:10.1208/s12248-017-0100-x · Cited by 54
Wang, Y., Fan, S., Xiao, D., Xie, F., Li, W., Zhong, W., & Zhou, X. (2019) · Cancers · doi:10.3390/cancers11070957 · Cited by 50
Lucas, A. T., Moody, A., Schorzman, A. N., & Zamboni, W. C. (2021) · Antibodies · doi:10.3390/antib10030030 · Cited by 40
Metadata
- Authors
- Peters, C., & Brown, S.
- Venue
- Bioscience Reports
- Publisher
- Portland Press Ltd.
- Published
- 2015-07-14
- Volume
- 35
- Issue
- 4
- ISSN
- 0144-8463 (ISSN-L)
- 1573-4935
- OpenAlex
- W2248346391
- Cited by
- 492
- References
- 198
- FWCI
- 30.30
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.